Analytical Data
-
Gene name
KCND2
- Application
-
Alternative Names
Voltage-gated potassium channel subunit Kv4.2
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZV8
-
Expression Region
406-630aa
-
Molecular Weight
27 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KCND2, also known as the potassium voltage-gated channel subfamily D member 2, is a gene that encodes a protein crucial for the modulation of neuronal excitability and cardiac rhythms. This voltage-gated potassium channel plays a significant role in regulating action potentials and neurotransmitter release in neurons. Dysfunctions or mutations in KCND2 have been associated with various neurological disorders, including epilepsy and ataxia, highlighting its importance in maintaining proper cellular function. The research on recombinant KCND2 protein is pivotal for understanding its structure-function relationship, as well as its role in physiological and pathological processes. Recombinant proteins allow scientists to study KCND2’s biophysical properties and interaction with other cellular components in vitro. Moreover, this research facilitates the development of therapeutic strategies for channelopathies associated with KCND2 dysfunction. Understanding the dynamics of KCND2 can also contribute to advancements in drug discovery, particularly in designing small molecules or modulators that may correct the dysfunctional biophysical properties caused by mutations. Thus, the study of KCND2 recombinant protein stands as a significant avenue in neuroscience and cardiology, holding potential for novel therapeutic interventions targeting potassium channel-related diseases.
